Vimarsana
Biggest News Aggregation in the World

Page 3 - Global Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Phase Today - Breaking & Trending Today

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments - Vimarsana News

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...

AstraZeneca's Wainua receives FDA approval in the US - Vimarsana News

AstraZeneca's Wainua receives FDA approval in the US

AstraZeneca's Wainua receives FDA approval in the US

AstraZeneca : Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Form 6-K -December 22, 2023 at 06:21 am EST - Vimarsana News

AstraZeneca : Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Form 6-K -December 22, 2023 at 06:21 am EST

A7568x FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria - Vimarsana News

Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - Vimarsana News

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 -- Adlai Nortye Ltd. , a clinical-stage biotechnology company focused on the development of innovative cancer therapies,...